INVESTORS

Raising $2.5M to nominate a PD-linked corneal repair lead

OcuRegen™ is a topical bioelectric therapy program for impaired corneal wound closure. The 24-week pre-seed plan is built to produce a lead-nomination decision using PD, ex vivo closure, tolerability, IP, and early FTO gates.

PRE-SEED DELIVERABLES

  • Reproducible corneal PD shift
    Predefined ΔTEP and Δion-flux response in corneal tissue.

  • PD-linked ex vivo closure
    Closure improvement versus vehicle or a pre-specified comparator.

  • Barrier and local tolerability
    No epithelial barrier, tear-film, or local tolerability red flag.

  • Protectable lead package
    Provisionals, early FTO readout, and differentiated formulation or chemistry rationale.

Contact

Investment snapshot

TARGET

PERSISTENT CORNEAL EPITHELIAL DEFECTS (PCED)

Non-healing corneal wounds (2+ weeks)

~100,000 cases/year

OUTPUT

DELIVERABLES

A nominated lead or a disciplined stop, supported by PD, closure, tolerability, provisional IP, and early FTO evidence.

GOAL

TARGET PRODUCT PROFILE (TPP)

≥50% faster closure vs. current standard of care (preclinical benchmarks)

EXPANSION

IMPAIRED HEALING CONDITIONS

Neurotrophic keratitis and adjacent ocular-surface impaired-healing settings after the PCED signal is established.

ASK

RAISE

$1M SAFE; 24-week pre-seed package

TIMING

WHY NOW

Improved PD measurement and ex vivo testing allow Galvanis to de-risk biology before larger animal and IND-enabling spend

Timeline

What this Round Must Prove and How we Plan to Protect the Program

IP STRATEGY

File provisional patents around:

  • Analog families

  • Ocular-local formulation / combination / use claims

  • Assay and gating know-how

  • Differentiated chemistry as it emerges

FREEDOM-TO-OPERATE (FTO)

Formal FTO work begins pre-seed / early seed, focused on ion-channel small molecules, ocular-local formulation, and corneal-repair use claims.

REGULATORY STRATEGY

PCED has precedent for Orphan Drug and Fast Track designation. We plan to pursue designation, so orphan exclusivity would be a potential benefit after approval.

REPRODUCIBLE PD SHIFT

Can the lead generate a reproducible, decision-useful corneal PD shift in human-relevant tissue?

PD to EX VIVO CLOSURE TRANSLATION

Does the PD signal translate into directional improvement in ex vivo closure versus vehicle or comparator?

LOCAL TOLERABILITY / BARRIER PRESERVATION

Can the candidate preserve barrier function and local tolerability while increasing wound-associated ion flux?

SUFFICIENT DIFFERENTIATION

Do the chemistry, formulation, and early IP/FTO profile justify rabbit work and a seed round?

Request materials

Deck and one pager are available for diligence. For discussion purposes only.

contact